This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks to Trade for Breakout Gains

Express Scripts

Express Scripts (ESRX - Get Report) is essentially forming the exact same setup right now. As with PAY, shares of this pharmacy benefit manager have been testing a resistance level into the fourth quarter of 2011, only to break out at the start of the year.

ESRX is no stranger to throwbacks -- in fact, shares actually staged a minor one immediately after the breakout above $48 in January. Now a second (more textbook) throwback is coming into play.

For Express Scripts, there's some added assurance that a throwback in shares will be successful. For starters, that $48 support level isn't just the breakout price, it's also the level where the 50 and 200-day moving averages are converging. That added support increases the probability that support will hold at $48.

Also in our favor is the fact that momentum, as measured by the 14-day RSI, is locked in an uptrend at the moment despite the return to test support. Regardless of those supporting factors, we'll still want to see a bounce before buying ESRX becomes a high-probability trade.

Express Scripts, one of 8 Big Acquirers of 2011, shows upon a list of 8 UBS Stock Picks for 2012. I also featured it recently in " 7 Hot Stocks on Traders' Radars."

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CVX $105.61 -1.20%
ESRX $87.68 2.70%
IP $55.51 0.54%
LNKD $253.28 -0.75%
PAY $34.54 -0.97%


DOW 17,864.82 -111.49 -0.62%
S&P 500 2,075.26 -10.98 -0.53%
NASDAQ 4,917.5350 -29.9060 -0.60%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs